CEL-SCI appoints Gail K. Naughton, Ph.D. to Board of Directors

CEL SCI CORP

Dr. Naughton founded Advanced Tissue Sciences (ATIS) and Histogen (HSTO), with 35+ years in regenerative medicine.
She holds over 125 U.S. and foreign patents and received the National Inventor of the Year award in 2000.
She serves on boards of Therapeutics MD (TXMD) and chairs the La Jolla Institute for Immunology board.
Appointment effective August 2, 2022.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gail K. Naughton, Ph.D.

Director

CVM · CEL SCI CORP

Effective: 2022-08-02
Filed: August 8, 2022, 7:59 PM ET

On August 2, 2022, CEL-SCI Corporation appointed Gail K. Naughton, Ph.D. to its Board of Directors.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gail K. Naughton, Ph.D. was appointed as Director at CEL SCI CORP.

Action: appointed
Role: Director

Exact text from the filing

On August 2, 2022, CEL-SCI Corporation appointed Gail K. Naughton, Ph.D. to its Board of Directors.

View on SEC.gov

CEL SCI CORP filing history →

Source: SEC EDGAR

accession 0001654954-22-010767

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.